arrow
J

Johanna C. Bendell

roche holding
H指数:82
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2024-12-310
OAAI
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

自噬基因Atg16l1的肿瘤内在表达抑制结直肠癌的抗肿瘤免疫

2023-09-2310
OAAI
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
2023-03-0117
PRE
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

nivolumab联合ipilimumab治疗晚期肾细胞癌脑转移患者的安全性和有效性: CheckMate 920

CANCER
IF5.1
2021-11-1632
OAAI
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels
2021-10-0837
OAAI
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)

结合肿瘤沉积和淋巴结转移数量以提高III期结肠癌的预后准确性: CALGB/SWOG 80702 III期研究 (Alliance) 的事后分析

2021-10-0161
OAAI
Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177
2021-07-011
OAAI
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

IDO-1抑制剂 (LY3381916) 作为单一疗法并与Anti-PD-L1抗体 (LY3300054) 联合用于晚期癌症患者的I期研究

2021-04-2715
PRE
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial

标准辅助治疗中添加塞来昔布与安慰剂对III期结肠癌患者无病生存期的影响CALGB/SWOG 80702 (Alliance) 随机临床试验

2021-04-0676
OA